# Jalid Sehouli

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jalid-sehouli/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,734 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 96 |
| i10-index | 583 |
| Last Known Institution | European Society of Gynaecological Oncology |
| OpenAlex ID | https://openalex.org/A5002555374 |
| ORCID iD | https://orcid.org/0000-0002-5963-6623 |
| Works | 1,725 |

## Researcher papers

Showing 12 of 17.

- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [Ovarian cancer](https://scholariq.org/papers/ovarian-cancer/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms](https://scholariq.org/papers/a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian/)
- [Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial](https://scholariq.org/papers/surgery-in-recurrent-ovarian-cancer-the-arbeitsgemeinschaft-gynaekologische/)
- [Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial](https://scholariq.org/papers/pembrolizumab-or-placebo-with-chemoradiotherapy-followed-by-pembrolizumab-or/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial](https://scholariq.org/papers/olaparib-plus-bevacizumab-first-line-maintenance-in-ovarian-cancer-final-overall/)
- [ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease](https://scholariq.org/papers/esgo-esmo-esp-consensus-conference-recommendations-on-ovarian-cancer-pathology/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [European Society of Gynaecological Oncology](https://scholariq.org/institutions/european-society-of-gynaecological-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.